Literature DB >> 12860998

Identification of an autoinhibitory domain of p21-activated protein kinase 5.

Yick-Pang Ching1, Veronica Y L Leong, Chi-Ming Wong, Hsiang-Fu Kung.   

Abstract

The p21-activated protein kinases (Paks) are serine/threonine protein kinases activated by binding to Rho family small GTPases, Rac and Cdc42. Recently, Pak family members have been subdivided into two groups, I and II. Group II Paks, including Pak4, Pak5, and Pak6, does not contain the highly conserved autoinhibitory domain that is found in the group I Paks members, i.e. Pak1, Pak2, and Pak3. In the present study, we have purified the glutathione S-transferase fusion form of Pak5 and shown for the first time that Pak5 autophosphorylation can be activated by GTP bound form of Cdc42. Mutation of histidine residues 19 and 22 to leucine on the p21-binding domain of Pak5 completely abolished the binding of Cdc42 and the Cdc42-mediated autophosphorylation. On the other hand, mutation of tyrosine 40 to cysteine of Cdc42 did not knockout the binding of Pak5. Analysis of C-terminal deletion mutants has identified an autoinhibitory fragment of Pak5 that is absent from other group II Pak family members. Taken together, these results suggest that Pak5, like Pak1, contains an autoinhibitory domain and its activity is regulated by Cdc42.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12860998     DOI: 10.1074/jbc.C300234200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells.

Authors:  Chi-Wai Lee; Leo Lap-Yan Wong; Edith Yuk-Ting Tse; Heong-Fai Liu; Veronica Yee-Law Leong; Joyce Man-Fong Lee; D Grahame Hardie; Irene Oi-Lin Ng; Yick-Pang Ching
Journal:  Cancer Res       Date:  2012-06-22       Impact factor: 12.701

2.  PAK6 targets to cell-cell adhesions through its N-terminus in a Cdc42-dependent manner to drive epithelial colony escape.

Authors:  Elizabeth M Morse; Xiaowen Sun; Jordan R Olberding; Byung Hak Ha; Titus J Boggon; David A Calderwood
Journal:  J Cell Sci       Date:  2015-11-23       Impact factor: 5.285

3.  Association of rs7754840 G/C polymorphisms in CDKAL1 with type 2 diabetes: a meta-analysis of 70141 subjects.

Authors:  Muhadasi Tuerxunyiming; Patamu Mohemaiti; Hamulati Wufuer; Awaguli Tuheti
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 4.  Signaling, Regulation, and Specificity of the Type II p21-activated Kinases.

Authors:  Byung Hak Ha; Elizabeth M Morse; Benjamin E Turk; Titus J Boggon
Journal:  J Biol Chem       Date:  2015-04-08       Impact factor: 5.157

Review 5.  Molecular pathways: targeting p21-activated kinase 1 signaling in cancer--opportunities, challenges, and limitations.

Authors:  Jeyanthy Eswaran; Da-Qiang Li; Anil Shah; Rakesh Kumar
Journal:  Clin Cancer Res       Date:  2012-05-17       Impact factor: 12.531

6.  PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable microtubules and dynamic actin.

Authors:  Dorthe Matenia; Bettina Griesshaber; Xiao-yu Li; Anja Thiessen; Cindy Johne; Jian Jiao; Eckhard Mandelkow; Eva-Maria Mandelkow
Journal:  Mol Biol Cell       Date:  2005-07-12       Impact factor: 4.138

Review 7.  P21 activated kinases: structure, regulation, and functions.

Authors:  Chetan K Rane; Audrey Minden
Journal:  Small GTPases       Date:  2014-03-21

8.  An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.

Authors:  Sean W Deacon; Alexander Beeser; Jami A Fukui; Ulrike E E Rennefahrt; Cynthia Myers; Jonathan Chernoff; Jeffrey R Peterson
Journal:  Chem Biol       Date:  2008-04

9.  Maternal pak4 expression is required for primitive myelopoiesis in zebrafish.

Authors:  Sheran H W Law; Thomas D Sargent
Journal:  Mech Dev       Date:  2012-09-29       Impact factor: 1.882

10.  Nucleocytoplasmic shuttling of Pak5 regulates its antiapoptotic properties.

Authors:  Sophie Cotteret; Jonathan Chernoff
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.